We were very pleased to read the excellent article by Abboud et al. Reference Abboud, Noronha and Diwadkar[1], who provided a thorough synthesis of the bio-behavioral relevance of motor dysfunction in schizophrenia by presenting basic movement physiology, schizophrenia-related brain mechanisms, and putative molecular pathways, particularly in the context of dopamine hypothesis. We fully agree with the authors that multistage approach on this particular research topic is important and their work will supplement calls arguing for renewed interest in this rapidly developing research domain Reference Abboud, Noronha and Diwadkar[1]. In this commentary we want to add some comments to the research framework outlined by Abboud et al., since there are a few key milestones that need to be reached in order to demonstrate the great value of the motor domain for both neuroscientific research and clinical practice Reference Hirjak, Thomann, Kubera, Wolf, Sambataro and Wolf[2]:

• • in order to better capture dimensionality among genuine and medication-induced motor symptoms in schizophrenia and related spectrum disorders, we need to make use of both clinical motor rating scales as well as novel instrumental assessments Reference van Harten, Walther, Kent, Sponheim and Mittal[3]. Motor symptoms are very suitable for instrumental assessment (IA), which has several advantages. It needs less training compared to clinical rating scales because IA lacks an observer bias, has a high intra- and inter-reliability and high sensitivity to detect even subclinical motor symptoms. Also, IA generates a continuous, much more precise rating instead of the ordinal value in most rating scales. The use of IA might contribute to a better characterization of both transdiagnostically and dimensionally occurring motor symptoms and signs such as tremor, balance, gait, rigidity, flexibility, motor stereotypes, compulsive and ritualistic behaviors, or motor impulsivity, respectively. The instruments that are already available show that quantifying motor symptoms instrumentally is a valid alternative to clinical rating scales and the enormous progress in technological (mobile) devices that can measure movements, opens new possibilities in the research to motor symptoms in these patients groups;

• • creating novel motor dimensions and categories based on objectively measurable parameters will open up new perspectives and targets for neuroscience research particularly in the context of early detection and intervention in psychosis and establishing neurobiologically reliable phenotypes;

• • IA provides the opportunity for assessment in real-world environments for a longer period and hence, it offers the opportunity to identify sociodemographic and clinical circumstances under which these subtypes of motor signs and symptoms occur at the most and their relationship over time with other psychiatric and somatic symptoms. IA might also help to identify subtle motor and sensory deficits in the period preceding manifest psychosis not visible to the naked eye. Eventually, IA of motor symptoms might help to differentiate between genuine/primary motor symptoms and drug-induced movement disorders more precisely;

• • from a practical perspective, downloadable applications or ‘apps’ for the smartphone could help patients to monitor their genuine motor symptoms and medication side-effects on a daily basis. IA might also help clinicians to objectively evaluate patient's complaints during daily rounds or after a particular period of time in the outpatient setting;

• • Abboud et al. Reference Abboud, Noronha and Diwadkar[1] referred to important regions within the motor system such as the primary motor cortex (M1), BA 6, comprised of the premotor cortex and Supplementary Motor Area (SMA), mid-cingulate cortex (dACC), the basal ganglia (e.g. globus pallidus, substantia nigra and sub-thalamic nuclei), and cerebellum, respectively. Abnormal morphology of these regions might contribute to neurological soft signs, abnormal involuntary movements, timing difficulties in movement execution, retarded finger tapping, reduced activation with wrist actigraphy, and reduced daily activity Reference Walther and Strik[4]. In particular, we believe that multiparametric mapping and connectivity measures of the above-mentioned regions might pave the way to thorough understanding of nigrostriatal and mesolimbic pathways. Beyond normal MRI, the combination of PET and MRI could visualize increased density of dopamine receptors in the striatum and fewer dopamine receptors in the dACC. This imaging technique will also work out the link between motor and cognitive symptoms (M1-SMA-Striatum-dACC) in psychiatric disorders;

• • future research needs to consider multimodality (both in terms of neuroimaging and behavior) and enrichment considering target populations who have been identified as exhibiting motor symptoms and signs;

• • most importantly, to achieve the above-mentioned goals, future studies should be based on motor dimension as supported by the RDoC initiative rather than on categorical diagnoses. We very much appreciate previous and ongoing endeavor to include a motor dimension within the RdoC research framework Reference Mittal, Bernard and Northoff[5]. Eventually, we’re looking forward to the outcomes of such investigations and believe that all of these issues will have profound implications for clinicians and patients alike.